User:Noxoug1/zilebesiran

zilebesiran, is an investigational RNAi therapeutic in development for the treatment of hypertension (high blood pressure). Zilebesiran has with a prolonged duration of action and inhibits hepatic angiotensinogen synthesis.

zilebesiran is currently in Phase 3 clinical trials in the United States in August 2023.

Medical uses
zilebesiran is indicated as monotherapy for the treatment of relapsing forms of multiple sclerosis, to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.

Tyruko is also indicated for inducing and maintaining clinical response and remission in adult patients with moderately to severely active Crohn's disease with evidence of inflammation who have had an inadequate response to, or are unable to tolerate, conventional Crohn's disease therapies and inhibitors of TNF-α (tumor necrosis factor, a substance in your body that causes inflammation).

The approval of Tyruko, a biosimilar to Tysabri (natalizumab), was based on evidence that showed there are no clinically meaningful differences between the two products in terms of safety, purity and potency.

Adverse effects
The most common adverse reactions were headache and fatigue in both the multiple sclerosis and Crohn's disease studies. Other common adverse reactions in the MS population were arthralgia, urinary tract infection, lower respiratory tract infection, gastroenteritis, vaginitis, depression, pain in extremity, abdominal discomfort, diarrhea NOS, and rash.

Other common adverse reactions in the CD population were upper respiratory tract infections and nausea

History
The FDA granted approval of Tyruko, the first biosimilar to Tysabri (natalizumab), to Sandoz Inc.